Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

InTouch Health: Santa Barbara, Calif.-based firm will use proceeds from a $12.1 mil. Series C financing for ongoing product development and expansion of its sales and marketing team. The firm recently launched its RP-7 remote presence robotic system. The funding was led by Galen Partners, which will contribute two board members, as well as existing investors Acacia Venture Partners and InvestCare Partners. InTouch founder Yulan Wang previously founded robotics company Computer Motion, which merged with Intuitive Surgical in 2003...

You may also be interested in...



Pre-Holiday Savings: Device Firms Prepare For Repatriation Tax Bonanza

Johnson & Johnson intends to "repatriate" as much as $10 bil. held by foreign subsidiaries following President Bush's Oct. 22 signing of the "JOBS" bill into law

MIT Spin-Off Evaluates Vascular Drug Delivery With $500,000 In VC Funds

Pervasis Therapeutics will rely in part on seed money from two Boston venture capital firms to help commercialize a vascular drug delivery device that would promote tissue healing

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Latest Headlines
See All
UsernamePublicRestriction

Register

MT022748

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel